Controversies in the management of clinical stage 1 testis cancer.
暂无分享,去创建一个
R. Huddart | P. Albers | P. Warde | L. Einhorn | Philippe Bédard | A. Hansen | P. Chung | M. Jewett | R. Hamilton | C. Kollmannsberger | C. Booth | L. Wood | G. Nason | C. Nichols | R. Rendon
[1] R. Huddart,et al. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis☆ , 2019, European urology.
[2] R. Hamilton,et al. Active surveillance in stage 1 disease: standard of care independent of risk factors? , 2019, Current opinion in urology.
[3] E. Castle,et al. Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes , 2019, World Journal of Urology.
[4] P. Warde,et al. Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option. , 2019, European urology focus.
[5] E. Bass,et al. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. , 2019, The Journal of urology.
[6] P. Warde,et al. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Hamilton,et al. Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer , 2019, Clinical genitourinary cancer.
[8] W. Mackillop,et al. Temporal trends in management and outcomes of testicular cancer: A population‐based study , 2018, Cancer.
[9] A. Morgans,et al. Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion. , 2018, Urologic oncology.
[10] K. Jensen,et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. , 2017, Urologic oncology.
[11] P. Albers,et al. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. , 2017, European urology.
[12] P. Pierorazio,et al. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. , 2017, European urology.
[13] P. Pierorazio,et al. Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer , 2017, The Journal of urology.
[14] C. Bokemeyer,et al. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. , 2017, European urology.
[15] R. Matulewicz,et al. The Evolving Management of Patients With Clinical Stage I Seminoma. , 2016, Urology.
[16] R. Wahlqvist,et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] A. Horwich,et al. Guidelines on Testicular Cancer: 2015 Update. , 2015, European urology.
[18] D. Serraino,et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. , 2015, European journal of cancer.
[19] S. Fosså,et al. Long-term Morbidity of Testicular Cancer Treatment. , 2015, The Urologic clinics of North America.
[20] S. Crabb,et al. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] T. Tandstad,et al. Primum Non Nocere: What Hurts in Clinical Stage I Testicular Cancer? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Warde,et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance , 2014, Cancer medicine.
[23] T. Powles,et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Hancock,et al. Testicular Cancer, Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[25] M. Ro̸rth,et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Daneshmand,et al. United States trends in patterns of care in clinical stage I testicular cancer: Results from the National Cancer Database (1998-2011). , 2014 .
[27] P. Warde,et al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy , 2013, BJU international.
[28] G. Bosl,et al. Optimal management of clinical stage I testis cancer: one size does not fit all. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Pond,et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. , 2011, European urology.
[30] G. Rustin,et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Huddart,et al. Canadian consensus guidelines for the management of testicular germ cell cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[32] D. Dearnaley,et al. Surveillance in stage I seminoma patients: a long-term assessment. , 2010, European urology.
[33] J. Chin,et al. Management of stage I non-seminomatous testicular cancer: a systematic review and meta-analysis. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[34] P. Warde,et al. Management of stage I seminomatous testicular cancer: a systematic review. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[35] R. Bremnes,et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Dearnaley,et al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy , 2006, BJU international.
[37] J. Carles,et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] A. Horwich,et al. Guidelines on testicular cancer. , 2005, European urology.
[39] John D Boice,et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.
[40] R. Motzer,et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. , 2005, The Journal of urology.
[41] M. Moore,et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. , 2005, The Canadian journal of urology.
[42] P. Albers,et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. , 2003, The Journal of urology.
[43] A. Horwich,et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Williams,et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.